Add a Beta-Blocker to Improve Blood Pressure Control and Reduce Cardiovascular Events
You should add a beta-blocker (bisoprolol, carvedilol, or metoprolol succinate) to this patient's regimen to address his uncontrolled hypertension and provide additional cardiovascular protection given his atrial fibrillation and heart failure with preserved ejection fraction (HFpEF).
Rationale for Beta-Blocker Addition
Your patient has HFpEF (EF 55-60%) with three compelling indications for beta-blocker therapy:
- Uncontrolled hypertension (150/80 mmHg despite ACE inhibitor)
- Atrial fibrillation requiring rate control
- Heart failure where beta-blockers reduce hospitalizations 1, 2
The 2016 ESC guidelines explicitly recommend beta-blockers in addition to ACE inhibitors for patients with heart failure to reduce hospitalization and death 2. While these recommendations were strongest for HFrEF, beta-blockers remain appropriate for HFpEF patients with specific indications like yours—particularly atrial fibrillation and hypertension 3, 4.
Specific Beta-Blocker Selection and Dosing
Choose one of these three evidence-based beta-blockers 1:
- Bisoprolol: Start 1.25 mg once daily, titrate to target 10 mg once daily
- Carvedilol: Start 3.125 mg twice daily, titrate to target 25-50 mg twice daily
- Metoprolol succinate (CR/XL): Start 12.5-25 mg once daily, titrate to target 200 mg once daily
Titration strategy: Double the dose every 2 weeks minimum, monitoring heart rate, blood pressure, and clinical status 1. Aim for target dose or the highest tolerated dose.
Why Not Other Options?
SGLT2 inhibitors (empagliflozin or dapagliflozin) would be excellent additions and are now guideline-recommended for HFpEF 5, 6, 7, 4. The 2022 AHA/ACC guidelines give SGLT2 inhibitors a Class 2a recommendation for HFpEF, with empagliflozin showing a 21% reduction in the composite endpoint of HF hospitalization or cardiovascular death in EMPEROR-Preserved 4. However, you specifically requested a "heart medication" and SGLT2 inhibitors are primarily antihyperglycemic agents, though they have profound cardiovascular benefits.
Sacubitril/valsartan (ARNI) showed modest benefits in HFpEF in PARAGON-HF but would require discontinuing his lisinopril 5, 7, 4. The benefit was greater in patients with lower EF (closer to 50%), and your patient's EF of 55-60% places him at the higher end where benefit is less certain 4.
Calcium channel blockers are explicitly not recommended in heart failure patients. Diltiazem and verapamil increase the risk of HF worsening and hospitalization 2. Even dihydropyridines should only be considered after optimizing other therapies 8.
Critical Monitoring Points
When initiating beta-blockers in this patient 1:
- Expect temporary worsening in 20-30% of patients during titration—this is manageable and not a reason to stop
- If congestion worsens: Double diuretic dose first; only halve beta-blocker if diuretics don't work
- If heart rate drops below 50 bpm with symptoms: Halve beta-blocker dose and review other rate-limiting drugs
- Asymptomatic hypotension: No change needed
- Symptomatic hypotension: Reconsider need for other vasodilators before reducing beta-blocker
Additional Considerations
Your patient's spironolactone 100 mg is already at a high dose. The typical dose for HFpEF is 12.5-50 mg daily 3, 9. Consider whether this high dose is contributing to his persistent edema through inadequate diuresis rather than helping it.
His lisinopril 5 mg is a low dose and could be uptitrated to 10-40 mg daily for better blood pressure control 10, though adding a beta-blocker addresses both his hypertension and atrial fibrillation simultaneously.
The persistent edema despite torsemide 30 mg suggests either inadequate diuresis or the need for combination diuretic therapy, but you've appropriately excluded additional diuretics from consideration.
Bottom Line
Start a beta-blocker immediately—it addresses all three of his cardiovascular conditions (hypertension, atrial fibrillation, HFpEF), has the strongest evidence base for "heart medications" in this clinical scenario, and will provide rate control for his atrial fibrillation while improving blood pressure. If you want to add a second agent after beta-blocker optimization, an SGLT2 inhibitor would be the next best choice based on recent HFpEF trials 5, 6, 7, 4.